As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...
The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...
HYDERABAD: IT and Industries Minister D Sridhar Babu on Thursday announced that the Congress government has secured ...
AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...
The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor. Both drugs have ...
Analysts had predicted that the new drug class would be priced at around $10,000 a year, so the premium being sought by Amgen and Sanofi in the US will increase calls for measures to pare down the ...
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus ...
In the wake of the U.S. Supreme Court’s decision in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023) (Amgen), in which the Court addressed whether Amgen’s functional antibody genus claims satisfy the ...